Pictet Asset Management Holding SA Sells 48,273 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Pictet Asset Management Holding SA lowered its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 4.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,090,173 shares of the biopharmaceutical company's stock after selling 48,273 shares during the period. Pictet Asset Management Holding SA owned 1.64% of Celldex Therapeutics worth $27,549,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the stock. Wellington Management Group LLP grew its holdings in Celldex Therapeutics by 14.5% during the third quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company's stock valued at $314,190,000 after purchasing an additional 1,167,659 shares during the period. American Century Companies Inc. grew its stake in shares of Celldex Therapeutics by 46.5% during the 4th quarter. American Century Companies Inc. now owns 608,457 shares of the biopharmaceutical company's stock worth $15,376,000 after acquiring an additional 193,093 shares during the period. Readystate Asset Management LP purchased a new stake in Celldex Therapeutics in the 3rd quarter worth about $6,102,000. Sovran Advisors LLC bought a new stake in Celldex Therapeutics in the 4th quarter valued at about $2,867,000. Finally, Sphera Funds Management LTD. lifted its holdings in Celldex Therapeutics by 35.5% during the third quarter. Sphera Funds Management LTD. now owns 419,103 shares of the biopharmaceutical company's stock valued at $14,245,000 after purchasing an additional 109,838 shares during the last quarter.

Celldex Therapeutics Price Performance

NASDAQ CLDX traded down $1.37 during trading on Friday, reaching $15.78. The company's stock had a trading volume of 1,183,579 shares, compared to its average volume of 868,596. The firm has a fifty day moving average of $21.18 and a 200 day moving average of $25.45. Celldex Therapeutics, Inc. has a one year low of $15.46 and a one year high of $47.00. The stock has a market capitalization of $1.05 billion, a PE ratio of -6.14 and a beta of 1.59.

Remove Ads

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.02. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The company had revenue of $1.18 million for the quarter, compared to analysts' expectations of $1.25 million. Research analysts expect that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on CLDX shares. Morgan Stanley initiated coverage on shares of Celldex Therapeutics in a research note on Thursday, March 20th. They issued an "overweight" rating and a $46.00 target price for the company. HC Wainwright reissued a "buy" rating and set a $80.00 target price on shares of Celldex Therapeutics in a report on Friday, February 28th. UBS Group began coverage on Celldex Therapeutics in a report on Thursday, February 13th. They issued a "buy" rating and a $44.00 price target for the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Finally, The Goldman Sachs Group cut their target price on Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Celldex Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $54.33.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.